Β-globin restored autologous HSC not checked

Bioray Laboratories

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“gene edited autologous hematopoietic stem cells with β-globin restoration”In the company’s words, NCT04205435 on ClinicalTrials.gov
Tested for
β-thalassemia Major
Main trialPhase 1/2
“This is a single center, single arm, open-label study to determine the safety and efficacy of β-globin restored autologous hematopoietic stem cells in β- thalassemia major patients with CVS-654 mutation.”In the company’s words, NCT04205435 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 1 Jun 2022 β-globin Restored Autologous HSC in β-thalassemia Major Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Β-globin restored autologous HSC

Following is part of Solo: you see every change to Β-globin restored autologous HSC the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in